Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 190 participants.

Also called NCT02786979

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 190 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02786979
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02786979. Randomized; no masking; primary purpose prevention. Start 2010-07 (registry gives no type); primary completion 2013-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Beraprost
Intervention (Drug)
Aspirin
Lead sponsor
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct02786979
Content hash
02c2d9342b4c76b4d3eceb9b2de3569987b6b1b408afbb09aa0d6277054f5de8